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Nonunion fractures and aseptic bone necrosis are two pathological conditions having some impairment of the cellular part of
the repair: a reduction of MSC and of the osteoblastic activation. Both are good candidates for cell-based therapies using stem
cells. We made a review of the published human trials. Only autologous bone marrow aspirate implantation was until now used.
In Nonunion, a direct injection—15 to 150ml—was made in 4 case series studies. In another, the bone marrow aspirate was
concentrated before injection. The results were good. In bone necrosis, only one level 1 study was published. The results at 24
months were positive in terms of reduction of the necrosis and appearance of collapse. In 3 case series studies, a treatment with
concentrated bone marrow aspirates was deemed useful with good results in 76 to 96%. These results are interesting but need
conﬁrmation by controlled studies.
1.Introduction
The physiological bone repair process is impaired in delayed
or nonunion (NU) fractures [1] and aseptic bone necrosis
(ON) [2].
Although the physiopathological factors are diﬀerent, in
both diseases, bone lesions are not repaired in the right time
nor in the right manner.
Bone healing is produced by a cellular mechanism
including mesenchymal stem cells (MSCs). The MSCs
need to be recruited in the pathological area. These non-
hematopoietic progenitor cells are able to be diﬀerentiated
in osteoblasts under the inﬂuence of growth factors such
as bone morphogenetic proteins (BMPs), platelet-derived
growth factor, transforming growth factor beta, insulin-like
growth factor, ﬁbroblast growth factor, and PTH.
MSC can be found mainly in bone marrow, but also
in fat tissue, synovium, periosteum, skeletal muscles, and
umbilical cord. Some recent data suggest that the osteogenic
diﬀerentiation capability of MSC from bone marrow and
from periosteum is higher than MSC from adipose tissues
[3].
Several methods could be used to increase MSC popu-
lation and its osteogenic diﬀerentiation in the pathological
area:
(i) a local injection of bone marrow aspirates,
(ii) a preliminary culture of the bone marrow aspirate to
increase the number of MSC cells,
(iii) a preliminary culture of the bone marrow aspirate to
p r o d u c ea ne x p a n s i o na n da no s t e o g e n i cd i ﬀerentia-
tion of the MSC,
(iv) a genetic modiﬁcation of the injected MSC to
increase the secretion of growth factors like BMP and
VEGF [4, 5].
In nonunion, the etiology is not clearly understood.
Excessive mechanical instability of the fracture, a reduction
of bone vascularity, and smoking are cited. Furthermore,
some genetic predisposition could exit. In atrophic NU sites,
osteoblast progenitor cells are signiﬁcantly reduced [6]. In
bone marrow from the iliac crest of atrophic NU bone
marrow-derivedmesenchymalstemcellsareinsmallernum-
ber and have a reduction of their proliferative capacity [7].2 Stem Cells International
In nontraumatic ON, apoptosis of osteocytes and can-
cellous bone lining cells in the necrotic lesion and also at
some distance from the lesion, in the proximal femur [8]
are increased. The replicative capacities of osteoblastic cells
obtained from the intertrochanteric area of the femur are
reduced in patients with ON [9]. The number and the
activity of ﬁbroblast colony-forming units, reﬂecting the
number of mesenchymal stem cells that could potentially
give rise to mature osteoblasts have been shown to be
decreased in ON [10, 11]. Moreover, the capillaries serving
as a conduit for the stem cells and bone cells needed in bone
repair in addition to providing blood supply could be altered
by emboli or thrombosis in ON [12].
In both pathological conditions, some impairment of the
cellularpartoftherepaircouldexist:areductionofMSCand
of the osteoblastic activation.
The best treatment remains to be found in both condi-
tions. Among the diﬀerent developed approaches, the cell-
based therapies to improve bone repair are presented and
seem to be promising. They are based on the concept of the
regenerative medicine and aim to recover an optimal bone
repair process.
This paper summarizes a review of the trials published in
this ﬁeld.
2. ClinicalTrialsinNonunion Fractures
A recent review of the current technologies in bone-healing
and repair didnot ﬁnd any human study of level-I evidence
concerning bone marrow aspirates, nor gene therapy [13].
Only a few studies support the therapeutic use of bone
marrow transplantation in human [2].
AsystematicreviewwasconductedusingPubMed,Med-
line. This research was completed checking references cited
in listed articles. The key words were “bone marrow”, “stem
cells”, “nonunion fractures”, and “cell-based treatment”.
Unlike animals, in humans, only bone marrow (BM)
aspirates implantations were until now used.
2.1. BMAspirate. Connolly andcoauthorsshould be the ﬁrst
to report results in a case of infected NU of the tibia [14]. In
a further report of the use of marrow graft for osteogenesis
from 1986 to 1995 including 100 patients having a tibial NU,
a good response was found in 80% [15]. No complications
were reported. The method used is made under general
anesthesia. The patient was placed in a prone position and
themarrowwasaspiratedin3–5-mlaliquots.Simultaneously
with the marrow aspiration, a second marrow needle was
inserted into the site of the nonunion to directly inject the
BM aspirate. The total injected volume was 100–150ml. In 2
cases a second injection was done. No reason for this second
injection was mentioned by the authors. The healing time
ranged from 6 to 10 months
In 1990, Healey et al. published good results in 7/8
cases of NU after BM aspirates injection in situ [16]. These
cases were all failure of osseous reconstruction (autogenous
iliac crest bone grafting) after lower-extremity resections
for sarcoma aﬀecting bone. The bone marrow, 56ml at the
beginning of the series to 3ml at the end, was aspirated from
the iliac crest under general anaesthesia, and directly injected
in NU, until a total of 50ml has been grafted. No heparin
was used to avoid potential impairment of bone healing
associatedwithheparin[17,18].In4casesasecondinjection
was made when no healing process was seen on review of
serial roentgenogram. The healing time ranged from 4 to 36
weeks (mean 18).
In 1993 Garg et al. applied a technique they tested earlier
in rabbits [19]. They grafted bone marrow percutaneously
in 20 ununited long bone fractures (15 in the tibia, 3 in
the humerus and 2 in the ulna). Under general anesthesia,
15–20ml of bone marrow aspirates (3-4 aspirations of 5ml)
from the posterior iliac crest was directly injected into the
NU sites twice, with an interval of 3 weeks. All cases were
immobilized in a plaster cast. In 17/20 cases a bone fusion
was observed after 5 months [6–10].
In 2005 Goel et al. presented results of BM grafting in
tibial NU [20]. Under local anesthesia, 3–5ml of marrow
was aspirated from the anterior iliac crest and injected
immediately percutaneously into and about the nonunion
site. Subsequent aspirations were performed 1cm posterior
to the previous site until a maximum of 15ml of marrow was
injected.Injectionswererepeatedat4–6weeksiftherewasno
radiological evidence of callus formation. The procedure was
considered a failure if there was no clinical and radiological
union at 6 weeks following the third injection. The results
revealed clinical and radiological bone union in 15 out of
20 patients (75%), with an average time to union following
the ﬁrst injection of 14 weeks. Four patients (20%) showed
no evidence of union and were considered a failure. There
were no cases of infection following the injection, and no
complications at the donor site.
2.2. Concentrated BM Aspirate. Only one trial using a
concentration of the BM aspirate was published. In 2005,
Hernigou et al. reported the results of a retrospective study
including 60 tibial NU [21]. Under general anesthesia,
300ml BM were aspirated from both anterior iliac crests,
then ﬁltered and concentrated by centrifugation on a cell
separator. The 50ml concentrated bone marrow was injected
in NU. Weight bearing was not allowed during minimum 1
month until a callus appeared. Failure was considered when
no healing existed after 6 months. In 53/60 patients, bone
union was obtained in mean 12 weeks (range 4–16 week).
They quantiﬁed the number of injected MSC and found a
signiﬁcant lower count of MSC in the negative cases.
2.3. Other. There was until now no human study using gene
modiﬁed MSC, expanded MSC or diﬀerentiated MSC in
osteoblasts. Only a recent publication concerns the eﬀect of
autologous osteoblast (OB) to improve the fracture healing
[22]. The autologous OB cells were obtained from a 4
weeks culture of 3–5ml bone marrow aspirate. A mixture
with 0,4ml (12 × 106 cells) and ﬁbrin was prepared and
injected under local anesthesia into the fracture area. In this
randomized study, a signiﬁcant fracture healing acceleration
was shown.Stem Cells International 3
3.ClinicalTrialsinOsteonecrosis
A systematic review was also conducted using Pub Med,
Medline. This research was completed checking references
c i t e di nl i s t e da r t i c l e s .T h ek e yw o r d sw e r e“ b o n em a r r o w ” ,
“stemcells”,“osteonecrosis”,“bonenecrosis”,“avascularbone
necrosis”, and “cell-based treatment”.
In 2002, Hernigou and Beaujean reported the results of
a noncontrolled study of femoral head osteonecrosis [23].
The patients were followed up from 5 to 11 years with a
mean of 7 years. When patients were treated before collapse,
hip replacement was done in 9 of the 145 hips. Total hip
replacement was necessary in 25 hips among the 44 hips
operated after collapse. The authors classiﬁed this study
in an evidence level III. But the study didnot have any
control!Theevaluationwasonlybasedonacomparisonwith
the estimated natural evolution of cases published in other
studies. The correct level of evidence seems to be level IV.
The method for implanting the bone marrow aspirate in the
necrotic area was the same as described for the same author
in NU. The volume of BM aspiration made under general
anesthesiawas300ml.Aﬁltrationandaconcentrationbycell
separatorwereperformed.Theﬁnalvolumetoinjectintothe
necrotic area was 50ml.
In 2004, Gangji et al. published a controlled, double
blind, prospective study including 18 femoral head ON
before collapse treated by core decompression using a 5mm
trephinewithorwithoutconcentratedBMaspirate[24].The
method to obtain and to prepare BM was the Hernigou’s
method. After 24 month followup, there was a signiﬁcant
reduction in pain and joint symptoms within the BM graft
group (P = .021). At 24 months, ﬁve of the eight hips in the
control group had deteriorated with appearance of a collapse
of the femoral head, whereas only one of the ten hips in the
BM graft group had progressed to this stage (P = .016). Sur-
vival analysis showed a signiﬁcant diﬀerence in the time to
collapsebetweenthetwogroups.Inaddition,intheBMgraft
group, the volume of the necrotic lesion decreased by 35%.
In 2008, a publication in Chinese presented a retrospec-
tive study using another method of treatment [25]. A 3-
tunnels core decompression was performed in the femoral
head to allow implantation of bone marrow MSC and
decalciﬁed bone matrix. Among the 87 patients (103 hips),
the average rate of excellent and good results (based on
clinical and radiological evaluation) were deemed to be 75,
7% after a followup of mean 26 months. No more details
were given.
In 2009, Wang et al. reported the results of 59 ON of
the femoral head (before or after collapse) in a prospective
noncontrolled study [26]. The 100–180ml BM aspirate was
concentratedto30–50ml.Theimplantationintothenecrotic
area was done through 2-3 holes made using a trocart with a
3.5mm outer diameter. The followup was mean 27 month
(range: 12–40). Clinically, the overall success was deemed in
80% and hip replacement was made in 7/59 hips (11,9%).
4. Discussion
In NU, this paper shows that the therapeutic eﬀect of
MSC is only supported by some studies using BM aspirate,
concentrated or not, of evidence level IV. Several diﬀerences
betweenthesestudiesmustbenoted.ThetypeofNUandthe
therapeutic methods were not the same. Diﬀerent methods
to harvest and to inject bone marrow were used. The volume
and the number of injected MSC (when evaluated) were
quite variable.
Good results were found in all. With small volume
(15–20ml) and without any concentration they were 83%
[19] and 75% [20]. With larger volumes (300ml) and after
concentration, the good results increased slightly to 88%
[21]. Clearly, the question of the best method, and the
interest of larger BM aspirate volumes are not resolved.
An additional question is the interest of an injection of
large volume in lesions having a smaller volume. What is
abouthoming andproliferationof injected MSC?Isthe bone
repair boosted by the injected MSC or by other components
oftheBMaspiratelikegrowthfactors?TrialsusingBMPhave
proven their eﬃcacy in 7 studies with level-1 evidence [13].
In ON, the eﬀect of BM implantation was tested in one
trial level-II evidence [24] and 3 trials level-IV [23]. The
method for harvesting and concentrating the bone marrow
astheinjectedvolumeasthemethodofimplantationwasthe
same in 2 studies but used 2 or 3 tunnels core in the 2 others.
Such results are very promising, but need to be conﬁrmed in
larger randomized control studies. The same answer about
the relationship between the injected volume and the lesion
volume needs to be studied.
Finally we do not ﬁnd data to conﬁrm that the therapeu-
tic eﬀect of BM aspirate should be due to its cellular part,
especially MSC and not to growth factors.
In conclusion, these reviews conﬁrm that BM aspirate
could induce bone repair in NU and ON. But the data are
verypreliminaryandalotofquestionsremaintobeclariﬁed.
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